It has been suggested that the presence of TNF-α in the TME after immunotherapies like toll-like receptor agonists, DC vaccines, and tumor vaccines might elevate the expression of TNFR2 on T-regs, thereby boosting their ability to suppress anti-cancer immune responses [196]. The gene discussed is TNFRSF1B; the disease is neoplasm.